CHRYSALIS BIOTHERAPEUTICS, INC.
GALVESTON, United States · Founded 2016 · $10.1M raised
- Headquarters
- GALVESTON, Texas
- Employees
- 1–10
- Founded
- 2016
- Business Model
- B2G
- Website
- chrysbio.com
- Total Funding
- $10.1M
- Last Round
- $10.1M Grant
- Rounds
- 1
About
Chrysalis BioTherapeutics is a clinical-stage biopharmaceutical company developing regenerative peptide drugs based on TP508 (Rusalatide acetate), a synthetic peptide that activates endothelial and stem cells to stimulate tissue repair. Lead programs target acute respiratory distress syndrome (ARDS) and radiation-induced injuries in collaboration with BARDA and NIAID. The company has raised over $30M primarily through non-dilutive government funding.
Summary
CHRYSALIS BIOTHERAPEUTICS, INC. is a Biotech company based in GALVESTON, United States, founded in 2016. It has raised $10.1M in total across 1 round. Investors include BARDA (Biomedical Advanced Research and Development Authority).
Tech & App Stack
5 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Unknown
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...